Claims for Patent: 5,821,122

Summary for Patent: 5,821,122

Title:	Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
Abstract:	New tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as NAG tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as NAG coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
Inventor(s):	Guilloux; Yannick (Nantes, FR), Jotereau; Francine (Nantes, FR), Boon-Falleur; Thierry (Brussels, BE), Lucas; Sophie (Brussels, BE), Brichard; Vincent (Brussels, BE)
Assignee:	Inserm (Institute Nat\'l de la Sante et de la Recherche . .) (Paris, FR)
Application Number:	08/487,135
Patent Claims:	1. An isolated nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO: 17. 2. An isolated nucleic acid molecule comprising a nucleotide sequence, the complimentary sequence of which hybridizes to the nucleotide sequence set forth in SEQ. ID. NO. 17 at 0.3 X SSC. 0.1% SDS. 3. An isolated molecule which is complementary to the nucleic acid molecule of claim 1, wherein said isolated molecule is mRNA or DNA. 4. A host cell transfected or transformed with the nucleic acid molecule of claim 1. 5. A host cell transfected or transformed with the nucleic acid molecule of claim 2. 6. An expression vector comprising the isolated nucleic acid molecule of claim 1 operably linked to a promoter. 7. An expression vector comprising the isolated nucleic acid molecule of claim 2 operably linked to a promoter. 8. The host cell of claim 4, wherein said host cell is a eukaryotic cell which expresses human leukocyte antigen-A2. 9. The host cell of claim 4, wherein said host cell is a prokaryotic cell which expresses human leukocyte antigen-A2. 10. The host cell of claim 5, wherein said host cell is a eukaryotic cell which expresses human leukocyte antigen-A2. 11. The host cell of claim 5, wherein said host cell is a prokaryotic cell which expresses human leukocyte antigen-A2. 12. The expression vector of claim 6, further comprising a nucleic acid molecule which codes for human leukocyte antigen-A2. 13. The expression vector of claim 7, further comprising a nucleic acid molecule which codes for human leukocyte antigen-A2. 14. An expression kit for purposes of expressing an intron-, expressed NAG tumor rejection antigen precursor comprising a separate portion of each of: (i) the isolated nucleic acid molecule of claim 1, and (ii) a nucleic acid molecule which codes for human leukocyte antigen-A2. 15. An expression kit for purposes of expressing an intron-, expressed NAG tumor rejection antigen precursor comprising a separate portion of each of: (i) the isolated nucleic acid molecule of claim 2, and (ii) a nucleic acid molecule which codes for human leukocyte antigen-A2. 16. The isolated nucleic acid molecule of claim 2, wherein said nucleic acid molecule codes for a tumor rejection antigen precursor (NAG).

Details for Patent 5,821,122

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26